IBC's 7th Annual Targeting Metabolic Disorders offers industry research scientists in depth science and technology solutions to enable the development of safe and effective obesity and diabetes therapeutics. It focuses on the measurement and understanding of the cardiovascular effects associated with patient's use of metabolic disease therapeutics. It is critical for the industry to gain these understandings so they may be reflected in the efficacy and safety profiles of drug products, tracked in clinical studies and properly presented in regulatory filings.